NovoCure’s EF-32 Optune® Trial Reaches Completion, Setting Up a Key Catalyst for NVCR Investors

NovoCure Ltd. (NVCR) announced an update on their ongoing clinical study.

The EF-32 pivotal study tests NovoCure Ltd.’s Optune® device in newly diagnosed glioblastoma. It compares standard care with radiation and temozolomide to the same care plus Optune®, aiming to see if the device can extend survival and improve outcomes in a tough brain cancer setting.

The treatment uses Optune®, a wearable device that sends low-intensity electric fields to the brain. The goal is to disrupt cancer cell division and boost the benefit of standard radiation and chemotherapy without adding major systemic side effects.

The trial is interventional and randomized, with patients split into two groups by chance. It is open label, so doctors and patients know which treatment is given, and the main goal is to test how well the treatment works rather than just how safe it is.

Patients either start Optune® at the same time as radiation and temozolomide or begin it after radiation ends. In both groups, Optune® and temozolomide continue until the tumor clearly worsens, which helps show how the timing and duration of device use may affect long term benefit.

The study was first submitted on July 9, 2020, marking the formal launch of clinical tracking. It recently posted an updated entry on March 27, 2026, which signals that data collection and review have progressed and that the record now reflects a completed trial status.

The trial itself is listed as completed, meaning patient follow up has finished and the core data set is locked. Primary completion and overall completion align with this status and indicate that the next catalyst for investors will be when top-line results or peer reviewed data are released or referenced by the company.

For NVCR, this update confirms another major late stage study has run its course, reducing clinical risk around execution. If outcomes are positive, it could support broader use of Optune® in the frontline setting, expand its addressable market, and strengthen the company’s revenue outlook over the medium term.

In the wider oncology device space, few direct competitors offer similar tumor treating field technologies, so a strong readout could reinforce NovoCure’s niche and help sentiment rebound after past volatility. Investors may watch closely for any signals on adoption, pricing power, and payer coverage as key drivers of long term stock performance.

The EF-32 study is now completed and recently updated, and further details are available on the ClinicalTrials.gov portal.

To learn more about NVCR’s potential, visit the NovoCure Ltd. drug pipeline page.